http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kailash Narayan,Sylvia van Dyk,David Bernshaw,Pearly Khaw,Linda Mileshkin,Srinivas Kondalsamy-Chennakesavan 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.3
Objective: The aim of this study was to report on the long-term results of transabdominal ultrasound guided conformal brachytherapy in patients with cervical cancer with respect to patterns of failures, treatment related toxicities and survival. Methods: Three hundred and nine patients with cervical cancer who presented to Institute between January 1999 and December 2008 were staged with magnetic resonance imaging and positron emission tomography and treated with external beam radiotherapy and high dose rate conformal image guided brachytherapy with curative intent. Follow-up data relating to sites of failure and toxicity was recorded prospectively. Results: Two hundred and ninety-two patients were available for analyses. The median (interquantile range) follow-up time was 4.1 years (range, 2.4 to 6.1 years). Five-year failure free survival and overall survival (OS) were 66% and 65%, respectively. Primary, pelvic, para-aortic, and distant failure were observed in 12.5%, 16.4%, 22%, and 23% of patients, respectively. In multivariate analysis, tumor volume and nodal disease related to survival, whereas local disease control and point A dose did not. Conclusion: Ultrasound guided conformal brachytherapy of cervix cancer has led to optimal local control and OS. The Melbourne protocol compares favorably to the more technically elaborate and expensive GEC-ESTRO recommendations. The Melbourne protocol’s technical simplicity with real-time imaging and treatment planning makes this a method of choice for treating patients with cervical cancer.
Ming Yin Lin,Srinivas Kondalsamy-Chennakesavan,David Bernshaw,Pearly Khaw,Kailash Narayan 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.6
Objective: The aim of this analysis was to examine the management of cervix cancer inelderly patients referred for radiotherapy and the results of treatment in terms of overallsurvival (OS), relapse-free survival (RFS), and treatment-related toxicities. Methods: Patients were eligible if they were aged ≥75 years, newly diagnosed with cervixcancer and referred for radiotherapy as part of their treatment. Patient details were retrievedfrom the gynaecology service database where clinical, histopathological treatment andfollow-up data were prospectively collected. Results: From 1998 to 2010, 126 patients aged ≥75 years, met selection criteria. Medianage was 81.5 years. Eighty-one patients had definitive radiotherapy, 10 received adjuvantradiotherapy and 35 had palliative radiotherapy. Seventy-one percent of patients had theInternational Federation of Gynecology and Obstetrics stage 1b–2b disease. Median followupwas 37 months. OS and RFS at 3 years among those treated with curative intent were66.6% and 75.9% respectively with majority of patients dying without any evidence of cervixcancer. Grade 2 or more late toxicities were: bladder 5%, bowel 11%, and vagina 27%. EasternCooperative Oncology Group (ECOG) status was a significant predictor of OS and RFS witheach unit increment in ECOG score increased the risk of death by 1.69 times (p<0.001). Conclusion: Following appropriate patient selection, elderly patients treated curativelywith radiotherapy for cervix cancer have good disease control. Palliative hypofractionatedregimens are well tolerated in patients unsuitable for radical treatment.